
Raimond takes helm at Nuclera
pharmafile | October 26, 2026 | Appointment | |ย ย Biotechnology, Diagnostics, appointmentsย
Nuclera, the biotechnology company enabling access to innovative protein technologies, has appointed Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, the companyโs co-founder and former CEO, becomes Chief Scientific and Business Officer, โcontinuing to provide scientific leadership while supporting market development and strategic partnershipsโ.
The firm said the leadership transition was the next phase in its evolution as it builds on more than a decade of expertise in cell-free protein synthesis, digital microfluidics and protein production, combining โCarlโs experience scaling life-science businesses with Michaelโs scientific leadership and deep understanding of Nucleraโs technology and marketsโ.
Pic: Martin Lopez
Related Content

Ofichem acquires US drug substance CDMO Kinentia
Ofichem has agreed to acquire Kinentia Biosciences, a US drug substance contract development and manufacturing …

bit.bio expands human heart cell portfolio through myriamed partnership
bit.bio has partnered with German biotechnology company myriamed to offer cryopreserved human induced pluripotent stem …

Could targeting the molecular causes of infertility finally transform IVF success rates?
By Dr Jordan Abdi Over the past two decades, demand for IVF has risen sharply …






